Literature DB >> 23427228

Spermatogonial stem cell preservation and transplantation: from research to clinic.

E Goossens1, D Van Saen, H Tournaye.   

Abstract

STUDY QUESTION: What issues remain to be solved before fertility preservation and transplantation can be offered to prepubertal boys? SUMMARY ANSWER: The main issues that need further investigation are malignant cell decontamination, improvement of in vivo fertility restoration and in vitro maturation. WHAT IS KNOWN ALREADY: Prepubertal boys who need gonadotoxic treatment might render sterile for the rest of their life. As these boys do not yet produce sperm cells, they cannot benefit from sperm banking. Spermatogonial stem cell (SSC) banking followed by autologous transplantation has been proposed as a fertility preservation strategy. But before this technique can be applied in the clinic, some important issues have to be resolved. STUDY DESIGN, SIZE DURATION: Original articles as well as review articles published in English were included in a search of the literature. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Relevant studies were selected by an extensive Medline search. Search terms were fertility preservation, cryopreservation, prepubertal, SSC, testis tissue, transplantation, grafting and in vitro spermatogenesis. The final number of studies selected for this review was 102. MAIN RESULTS AND THE ROLE OF CHANCE: Cryopreservation protocols for testicular tissue have been developed and are already being used in the clinic. Since the efficiency and safety of SSC transplantation have been reported in mice, transplantation methods are now being adapted to the human testes. Very recently, a few publications reported on in vitro spermatogenesis in mice, but this technique is still far from being applied in a clinical setting. LIMITATIONS, REASONS FOR CAUTION: Using tissue from cancer patients holds a potential risk for contamination of the collected testicular tissue. Therefore, it is of immense importance to separate malignant cells from the cell suspension before transplantation. Because biopsies obtained from young boys are small and contain only few SSCs, propagation of these cells in vitro will be necessary. WIDER IMPLICATIONS OF THE
FINDINGS: The ultimate use of the banked tissue will depend on the patient's disease. If the patient was suffering from a non-malignant disease, tissue grafting might be offered. In cancer patients, decontaminated cell suspensions will be injected in the testis. For patients with Klinefelter syndrome, the only option would be in vitro spermatogenesis. However, at present, restoring fertility in cancer and Klinefelter patients is not yet possible. STUDY FUNDING/COMPETING INTEREST(S): Research Foundation, Flanders (G.0385.08 to H.T.), the Institute for the Agency for Innovation, Belgium (IWT/SB/111245 to E.G.), the Flemish League against Cancer (to E.G.), Kom op tegen kanker (G.0547.11 to H.T.) and the Fund Willy Gepts (to HT). E.G. is a Postdoctoral Fellow of the FWO, Research Foundation, Flanders. There are no conflicts of interest.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427228     DOI: 10.1093/humrep/det039

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  38 in total

1.  In vitro culture and characterization of spermatogonial stem cells on Sertoli cell feeder layer in goat (Capra hircus).

Authors:  R Kumar Pramod; Abhijit Mitra
Journal:  J Assist Reprod Genet       Date:  2014-06-24       Impact factor: 3.412

2.  Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.

Authors:  A Balduzzi; J-H Dalle; K Jahnukainen; M von Wolff; G Lucchini; M Ifversen; K T Macklon; C Poirot; T Diesch; A Jarisch; D Bresters; I Yaniv; B Gibson; A M Willasch; R Fadini; L Ferrari; A Lawitschka; A Ahler; N Sänger; S Corbacioglu; M Ansari; R Moffat; A Dalissier; E Beohou; P Sedlacek; A Lankester; C D De Heredia Rubio; K Vettenranta; J Wachowiak; A Yesilipek; E Trigoso; T Klingebiel; C Peters; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

Review 3.  Beyond the mouse monopoly: studying the male germ line in domestic animal models.

Authors:  Raquel González; Ina Dobrinski
Journal:  ILAR J       Date:  2015

Review 4.  Testicular Tissue Cryopreservation and Ethical Considerations: A Scoping Review.

Authors:  Angel Petropanagos
Journal:  J Bioeth Inq       Date:  2017-03-28       Impact factor: 1.352

5.  Preserving children's fertility: two tales about children's right to an open future and the margins of parental obligations.

Authors:  Daniela Cutas; Kristien Hens
Journal:  Med Health Care Philos       Date:  2015-05

6.  Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.

Authors:  Guido De Wert; Björn Heindryckx; Guido Pennings; Angus Clarke; Ursula Eichenlaub-Ritter; Carla G van El; Francesca Forzano; Mariëtte Goddijn; Heidi C Howard; Dragica Radojkovic; Emmanuelle Rial-Sebbag; Wybo Dondorp; Basil C Tarlatzis; Martina C Cornel
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

Review 7.  Germline stem cells: toward the regeneration of spermatogenesis.

Authors:  Hanna Valli; Bart T Phillips; Gunapala Shetty; James A Byrne; Amander T Clark; Marvin L Meistrich; Kyle E Orwig
Journal:  Fertil Steril       Date:  2013-12-05       Impact factor: 7.329

Review 8.  Fertility preservation in men with cancer.

Authors:  Koji Chiba; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2014-04-26

9.  Spermatogonial stem cells: Current biotechnological advances in reproduction and regenerative medicine.

Authors:  Pedro Manuel Aponte
Journal:  World J Stem Cells       Date:  2015-05-26       Impact factor: 5.326

Review 10.  Experimental methods to preserve male fertility and treat male factor infertility.

Authors:  Kathrin Gassei; Kyle E Orwig
Journal:  Fertil Steril       Date:  2015-12-30       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.